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Background:  Anti-HIV-1  IgM antibody  is  an  important  immunoassay  target  for early  HIV  antibody  detec-
tion.
Objectives:  The  objective  of this study  is  to determine  if the  early  HIV  antibody  sensitivity  of  the 60  s INSTI
test  is due  to detection  of anti-HIV-1  IgM  in  addition  to  IgG.
Study  Design:  To  demonstrate  HIV  gp41  IgM  antibody  capture  by the  INSTI  HIV-1  gp41 recombinant  anti-
gen,  an  HIV-IgM  ELISA  was  conducted  with  commercial  HIV-1  seroconversion  samples.  To  demonstrate
that  the INSTI  dye-labelled  Protein  A-based  colour  developer  (CD)  has  afﬁnity  to  human  IgM,  commercial
preparations  of puriﬁed  human  immunoglobulins  (IgM,  IgD, IgA,  IgE,  and  IgG)  were  blotted  onto  nitro-
cellulose  (NC)  and  probed  with  the CD to observe  spot  development.  To  determine  that  INSTI is able  to
detect  anti-HIV-1  IgM  antibody,  early  seroconversion  samples,  were  tested  for  reduced  INSTI  test  spot
intensity  following  IgM removal.
Results:  The  gp41-based  HIV-IgM  ELISA  results  for 6  early  seroconversion  samples  that  were  INSTI  positive
determined  that  the  assay  signal  was  due to anti-HIV-1  IgM  antibody  capture  by  the immobilised  gp41
antigen.  The  dye-labelled  Protein-A  used  in  the INSTI  CD  produced  distinct  spots  for  puriﬁed  IgM,  IgA,  and
IgG  blotted  on the  NC  membrane.  Following  IgM removal  from  21HIV-1  positive  seroconversion  samples
with  known  or undetermined  anti-HIV-1  IgM  levels  that  were  western  blot  negative  or indeterminate,
all  samples  had  signiﬁcantly  reduced  INSTI  test  spot  intensity.
Conclusions:  The  INSTI HIV-1/HIV-2  Antibody  Test  is  shown  to  detect  anti-HIV-1  IgM  antibodies  in early
HIV  infection  which  enhances  its utility  in  early  HIV diagnosis.
©  2015  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the CC. Background
Early detection of HIV is an important component of HIV pre-
ention and control programs since identiﬁcation of HIV infected
ndividuals in the early stages can support effective transmission
eduction, intervention and care strategies [1,2]. Different diag-
ostic testing algorithms exist for HIV detection; however, those
hat utilize rapid point-of-care tests (RPOCTs) for HIV have advan-
ages in terms of time-to-results, accessibility to testing programs,
nd ease of use in comparison to the standard laboratory-based
ests [3,4]. Among these, the FDA-approved, US Health and Human
ervices Clinical Laboratories Improvement Amendment (CLIA)
aived INSTITM HIV-1/HIV-2 Antibody Test (“INSTI”, bioLytical Lab-
ratories, Richmond BC) is capable of providing results in as little
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y-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
as 60 s [5]. The INSTI test employs a ﬂow-through design format,
which facilitates the more rapid time to results while maintaining
a high degree of sensitivity and speciﬁcity [6,7]. Moreover, INSTI
has shown an ability to detect early HIV-1 seroconversion in a com-
parative study using characterized, sequentially collected, archived
plasma samples from individuals who seroconverted for HIV-1 in
British Columbia, Canada [2]. Additionally, in a report posted by
the US Centers for Disease Control, Atlanta, INSTI was more sen-
sitive during early infection in comparison to other FDA approved
second and third generation rapid HIV antibody tests, detecting
HIV antibody a median 13.5 days after RNA detection (CDC unpub-
lished data) [5]. Under the Fiebig classiﬁcation system based on test
results for markers of the virus and the immune response, only the
most sensitive HIV antibody tests are able to detect HIV antibody in
samples that meet Fiebig class III staging, while HIV Western Blot
is still negative, and anti-HIV-I-IgM is positive [8] (Table 1). We
hypothesized that INSTI capacity for early HIV antibody detection,
equivalent to a Fiebig class III staging, is due to its ability to detect
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Table  1
Stages of primary HIV infection based on laboratory tests [8].
Stages HIV-RNA P24 Ag EIA-enzyme immunoassay Western blot (IgG)
I + – – –
II  + + – –
III  + + IgM positive –
IV  + +/− IgM positive Indeterminate
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Fig. 1. Enzyme-linked immunosorbent assay (ELISA) method for detecting anti-HIV-
1  IgM antibody captured by membrane-bound recombinant gp41.V  + +/− + +
VI  + +/− + +
he presence of anti-HIV-1 IgM antibody while HIV-speciﬁc IgG is
till negative or indeterminate. The stages of primary HIV infection,
ccording to the Fiebig model, are presented in Table 1.
As with every viral infection, IgM is the ﬁrst immunoglobulin
roduct of the humoral system in HIV-1 infection [1,9]. The ability
f a gp41 antigen-based HIV antibody assay to speciﬁcally detect
nti-HIV-1 IgM antibody would be an important characteristic of a
POCT for the early diagnosis of HIV infection [1]. Therefore, accu-
ate detection of anti-HIV-1 IgM antibody can narrow the serologic
indow for early detection of HIV infection and reduce the gap
etween p24Ag detection and HIV antibody detection even further
1,9].
. Objectives
The objective of this study was to determine if the sensitivity
f INSTI for early HIV-1 antibody detection is based on the assay’s
bility to capture and visualize reactions from the IgM class of anti-
odies to HIV-1 gp41 during early seroconversion. To demonstrate
his, it was necessary to: (1) provide evidence that the recombinant
p41 protein used in INSTI has afﬁnity for the IgM class of spe-
iﬁc HIV antibodies; (2) demonstrate that the protein-A/indigo blue
ye conjugate used to visualize HIV antibody reactions in the INSTI
ethod also has afﬁnity to human IgM; (3) demonstrate that early
eroconversion samples that were reactive with INSTI became non-
eactive or had signiﬁcantly reduced signal intensity upon removal
f anti-HIV-1 IgM antibody.
. Method & materials
.1. INSTI
INSTI is a manual, visually read, ﬂow-through RPOCT for the
ualitative detection of HIV-1and/or HIV-2 antibodies in 50 l of
uman blood, whole blood, serum and plasma in as little as 60 s
10].
.2. Anti-HIV-1 IgM enzyme-linked immunosorbent assay (ELISA)
Fig. 1)
In this ELISA method, 0.5 l of gp41 recombinant protein at a
oncentration of 1 mg/ml  (GenWay Biotech Inc., San Diego, CA)
as spotted onto unbacked Hi-Flow (HF-180) nitrocellulose mem-
ranes (EMD Millipore Billerica, MD,  USA). Bovine Serum Albumin
BSA, 1.0%) in Tris-NaCl buffer (TBS, Tris 50 mM,  NaCl 150 mM,  PH
.7) was used as a blocking agent. Primary antibodies, diluted 1:100
n 1% (BSA-TBS) were applied to the antigen-spotted membranes.
ommercial seroconversion panel specimens (SeraCare Life Sci-
nces HQ, MA)  that indicated high levels of HIV-IgM antibody on
he panel datasheets as shown in Fig. 2, HIV-IgG antibody positive
erum (ProMedDx, MA), and HIV negative serum (ProMedDx, MA)
ere used as primary antibodies. Mouse monoclonal anti-human
gM (Novus Biologicals), diluted 1:10,000 in 1% BSA-TBS, was
sed as a secondary antibody, and ﬁnally horseradish peroxidase-
abelled (HRPO) rabbit polyclonal anti mouse IgG (Sigma–Aldrich),In  this method the primary HIV-IgM antibody bound to the gp41 is detected by
mouse anti-human anti-IgM antibody and visualized by the HRPO conjugated anti-
body/substrate.
was used as a conjugate antibody and developed with a chemi-
luminescence reagent for 30 s. The assay design is provided in Fig. 1.
3.3. Detection of different human Igs by INSTI Colour Developer
To provide indication that the standard colour developer
solution from INSTI has binding afﬁnity to human IgM, 0.5 l
of ﬁve different classes of commercial puriﬁed single human
immunoglobulin preparations, IgM (Sigma–Aldrich), IgD (Athens
Research & Technology Inc.), IgA (Bethyl laboratories Inc.), IgE (AbD
Serotec Bio-Rad), and IgG (Bethyl laboratories Inc.) at a concen-
tration of 1 mg/ml  were blotted onto nitrocellulose membranes
and allowed to dry. The standard volume of 1.5 ml  of INSTI colour
developer was  added and allowed to ﬂow through the membrane
followed by 1.5 ml  of INSTI clarifying solution.
3.4. Removal of IgM antibody
The MACS Human anti-IgM MicroBeads and magnetic separa-
tion (MS) with MS  column system (Miltenyi Biotec Inc., San Diego
CA), was applied for total IgM removal. Aliquots of 50 l from each
seroconversion or control sample, or 50 l of puriﬁed human IgM
were diluted in 1.5 ml  of INSTI solution 1, and 20 l of anti-human
IgM MicroBeads was added to the diluted seroconversion sam-
ple. After 30 min  incubation at 4 ◦C, IgM from the diluted samples
that was  bound to human the anti-IgM MicroBeads was  extracted
using an MS  column equipped with a magnetic separator. The
IgM extraction step was repeated three times to ensure maxi-
mum  yield. Finally, the IgM-extracted seroconversion and control
samples were tested with INSTI. The same untreated samples at
equivalent dilution were also tested with INSTI to compare to the
IgM-extracted counterparts for visible signal intensities.
4. Study design
4.1. Anti-HIV-1 IgM ELISA to detect the afﬁnity of gp41 to HIV-1
IgM
HIV-1 positive seroconversion samples containing high levels of
HIV-IgM (SeraCare Life Sciences HQ, MA,  Fig. 2) were used as pri-
mary antibody. As a negative control, seroconversion panel samples
which were HIV antibody negative, but HIV-RNA or P24 anti-
gen positive, and three commercial HIV negative plasma samples
(ProMedDx, MA), were used as the primary antibody. Any anti-HIV-
1 IgM antibody present in the primary specimen would produce a
visible colour reaction at the antigen spot location and indicate that
of Clinical Virology 71 (2015) 67–72 69
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Fig. 3. Relative sensitivity of INSTI gp41 antigen to HIV-IgM antibody levels.N. Moshgabadi et al. / Journal 
he solid phase-bound gp41 antigen effectively captures anti-HIV-1
gM antibody.
.2. Detection of human IgM by INSTI colour developer
The presence of any visible blue dots at the Ig blotted spot loca-
ions indicate a direct afﬁnity of the INSTI colour developer to the
mmunoglobulin class [11,12].
.3. Detection of anti-HIV-1 IgM antibody by the INSTI
To demonstrate that the INSTI detects anti-HIV-1 IgM anti-
ody due to the combined afﬁnities of its HIV-1 gp41 antigen and
rotein-A indicator solution to human IgM, total IgM was  removed
y anti-IgM microbeads from 21 known INSTI positive serocon-
ersion samples that were WB (IgG) negative or indeterminate to
bserve for signiﬁcant reduction or disappearance of spot intensity
ollowing INSTI testing. As a control, 5 later-bleed samples from
he seroconversion panels, containing little or no anti-HIV-1 IgM
ntibody but high levels of anti-HIV-1 IgG antibodies [11,12] were
sed in the same method.
. Results
.1. ELISA method to demonstrate INSTI gp41 antigen afﬁnity to
IV-IgM
Seroconversion samples 944-06 and 943-07, each contain-
ng high levels of IgM were reacted with duplicate spots of the
embrane-bound INSTI gp41 antigen and observed for the pres-
nce of visible colour reaction upon completion of the ELISA
ethod. As shown in Fig. 2, both samples produced visible
urple-coloured spots when reacted with the secondary mouse
nti-human IgM followed by conjugated rabbit polyclonal anti-
ouse antibody and substrate. As a control for anti-HIV-1 IgM
ntibody speciﬁcity, HIV negative samples (B6390, B6392, B6888)
nd HIV antibody negative/RNA, P24Ag positive plasma samples
PRB945-02), and HIV antibody negative and RNA positive plasma
ample (PRB944-02) showed no visible test spots (non-reactive) in
his ELISA procedure.
The intensity of the anti-HIV-1 IgM antibody positive test spot
as proportional to the relative amount of IgM present in the sam-
le; Fig. 3 illustrating the relative sensitivity of INSTI to HIV-1-IgM.
Sequential samples from two commercial seroconversion pan-
ls with progressively reduced levels of anti-HIV-1 IgM antibody
ig. 2. The ability of INSTI HIV-1 gp41 antigens to bind anti-HIV-1 IgM antibody.
nti-HIV-1 IgM antibody ELISA results for HIV positive seroconversion samples
ith a high amount of HIV-IgM (944-06, 943-07) showed clearly visible spots on
he  membrane. HIV antibody negative plasma samples from seroconversion panels
nd HIV negative serum showed no visible spot on membrane. In-House IgM data
as  provided with the panel datasheet from SeraCare Life Sciences. N: negative; P:
ositive; S/CO: signal/cutoff.The  intensity of the anti-HIV-1 IgM antibody ELISA positive test spot is proportional
to  the relative IgM levels found in the seroconversion panel samples 940-04, 940-08,
934-02, 934-03. N: negative; P: positive; S/CO: signal/cutoff.
across patient bleeds as shown in Fig. 3 Table were tested (PRB934
and PRB940, Fig. 3). Anti HIV-1 ELISA testing showed signiﬁcant
reduction or disappearance of test spot intensity across sequen-
tial samples, indicating that anti-HIV-1 IgM antibody ELISA spot
intensity was  proportional to the level of anti-HIV-1 IgM antibody
present in the primary antibody sample.
5.2. The ability of INSTI colour developer to detect human puriﬁed
IgM antibody
In INSTI, the test spot captures HIV-1/2 antibodies which are
present in the test sample and then visualized by the protein-A-
indigo blue colour developer producing a blue colour signal on the
membrane. After reacting this protein A-indigo colour developer
directly against the different human immunoglobulin classes blot-
ted onto nitrocellulose, puriﬁed IgM, IgA and IgG showed a blue spot
while IgD and IgE did not show any spot (Fig. 4). Thus, protein-A-
indigo in the INSTI colour developer binds to human IgM, IgG, and
IgA antibodies but not to IgD or IgE antibodies.
5.3. The ability of INSTI to detect anti-HIV-1 IgM
The results for the IgM-extracted samples before and after
processing with the anti-IgM MicroBeads followed by magnetic
separation are presented in Table 2.
Of the 21HIV-1 positive, WB negative or indeterminate com-
mercial seroconversion samples from which IgM was extracted,
all showed a signiﬁcant reduction of INSTI spot intensity when
tested following IgM extraction compared to test spot intensity
before extraction. Of note, 10/21 samples became INSTI negative
after IgM extraction, indicating that the antibody response to HIV
in these early seroconversion samples was  likely entirely due to
anti-HIV-1 IgM antibody. Interestingly four of the seroconversion
samples tested in this study, 924-06, 943-06, and 927-03 and 928-
02 provided datasheet information consistent with the Fiebig class
III staging description. Three out of four samples (ie. 924-06, 943-
06, and 928-02) showed dot disappearance, and the fourth sample
(i.e., 927-03) showed more the 50% spot intensity reduction follow-
ing IgM removal, indicating that INSTI is capable of being reactive
during class III staging of early HIV seroconversion where Western
Blot is negative. Two  additional Western Blot negative Serocon-
version samples (922-02, and 922-03) that did not undergo IgM
removal also showed INSTI positive results.
The 5HIV antibody positive samples from late seroconversion,
which contain only HIV IgG antibodies, showed no difference in
INSTI test spot intensity before and after IgM extraction. Addition-
ally, to demonstrate the ability of the MACS kit to remove only IgM,
the IgM extraction process was  applied to a puriﬁed human IgM
(Sigma) preparation as well as an HIV-IgG antibody positive serum
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Fig. 4. The afﬁnity of INSTI solution 2 (solution 2-ProA) to bind to human immunoglobulin classes.
INSTI protein-A/indigo solution produces visible reactions to human IgA, IgG, IgM, but not to IgD, IgE.
Table 2
Summary of INSTI test results on Commercial HIV-1 Seroconversion Samples before and after IgM removal. A 100% reduction in INSTI intensity is interpreted as non-reactive,
ie  no visible test spot. 21 INSTI positive samples that were WB (IgG) indeterminate or negative showed reduction or disappearance of dot intensity; 5 samples that were WB
(IgG)  positive did not show any reduction in spot intensity after IgM removal. P: positive; N: negative; IND: indeterminant; ND: in-house IgM assay not determined; *: meets
Fiebig  class III staging deﬁnition.
Sample # Western Blot (IgG) for INSTI positive samples In house-IgM Test dot disappeared after IgM removal in%
914-01 IND ND 100%
914-02 IND ND >%50
914-03 IND ND 100%
924-06* N P 100%
924-07 IND P >%50
924-08 IND P >%50
925-05 IND P 100%
925-06 IND P >%50
927-03* N P >%50
927-04 IND P 100%
928-02* N P 100%
934-02 IND ND >%50
934-03 IND P >%50
938-03 IND P 100%
940-03 IND P 100%
940-04 IND P >%50
940-05 IND ND <%50
941-04 IND P >50%
943-06* N P 100%
944-05 IND P 100%
950-04 N ND >%50
914-04 P ND 0%
914-05 P ND 0%
s
i
h
e
o
a
t904-04 P 
904-05 P 
919-03 P 
ample with no known HIV IgM as a control. The results are shown
n Fig. 5.
When the INSTI solutions were applied to 50 l of puriﬁed
uman IgM added to a protein
A-dot blotted nitrocellulose membrane before and after IgM
xtraction, a signiﬁcant reduction in protein-A spot intensity was
bserved. Conversely, no reduction of protein-A spot or HIV-1 gp41
ntigen spot intensities were observed following INSTI testing of
he IgM-extracted HIV-IgG positive sample (Fig. 5B).
Fig. 5. Images of INSTI results before and after the IgM removal procesND 0%
ND 0%
ND 0%
An additional example where INSTI reactive results are
determined by the presence of anti-HIV-1 IgM antibodies is
presented in Fig. 6. In this example, INSTI was  reactive for
a commercial seroconversion sample (PRB 928-2) that con-
tained measureable levels of anti-HIV-1 IgM but both HIV-IgA
and Western Blot (IgG) negative were negative according to
sample datasheet provided by SeraCare Life Sciences. Upon
MACS extraction of IgM, this sample became INSTI non-
reactive.
s for puriﬁed human IgM (5A) and HIV-IgG positive serum (5B).
N. Moshgabadi et al. / Journal of Clin
Fig. 6. The ability of INSTI to detect anti-HIV IgM antibody.
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. Discussion
Studies have shown that newer-generation assays, including
hird-generation assays, can detect HIV antibody in as little as 3–4
eeks after infection [13]. Combination HIV antibody/p24 Anti-
en tests, commonly referred to as fourth-generation tests, have
ecome the gold standard for laboratory-based testing algorithms
ue to their ability to capture p24Ag in the pre-antibody window
eriod of infection [14]. However, performance of fourth genera-
ion assays for HIV antigen detection in RPOCT formats has been
nconsistent [15–18]. Most approved rapid HIV antibody tests cur-
ently on the market are highly sensitive for detecting HIV infection,
ut they vary in their ability to detect low levels of antibody,
uch as those occurring before complete seroconversion [19]. Dur-
ng this early seroconversion period, IgM antibodies can reach
etectable levels within the ﬁrst three weeks following infection
11]; however, these HIV-speciﬁc IgM antibodies are not produced
onsistently during early infection [11,20]. Nevertheless, the abil-
ty of some HIV assays to detect IgM antibody simultaneously or in
dvance of immunoglobulin G (IgG) may  be responsible for their
igher analytical sensitivity. One such assay, INSTI, has repeatedly
hown sensitivity to HIV-1 antibody detection in samples collected
uring early seroconversion [2,7].
Our results have shown that INSTI’s design format enables it
o capture anti-HIV-1 IgM antibodies consistently when present in
arly seroconversion samples. The results from this study as shown
n Fig. 2 and Fig. 3 clearly demonstrated the ability of INSTI’s recom-
inant HIV-1 gp41 antigen to bind anti-HIV-1 IgM in characterized
ommercial early seroconversion samples. These ﬁndings are con-
istent with a determination by Tomaras et al. that the ﬁrst free
lasma anti-HIV-1 antibody was to gp41, which appeared 13 days
fter the appearance of plasma virus [21]. Studies have shown that
rotein A has strong afﬁnity for IgG and variable afﬁnity for IgM
nd IgA with no afﬁnity for IgD and IgE [23]. Coupled with the IgM-
fﬁnity of the protein-A based INSTI Colour Developer, as shown
n Fig. 4, INSTI is highly optimized for anti-HIV-1 IgM detection. In
ddition, the relatively large sample size of 50 l may  compensate
or the lower afﬁnity for IgM compared to IgG.
This ability of INSTI to detect anti-HIV-1 IgM was conclusively
stablished when INSTI was conducted on early seroconversion
amples before and after IgM extraction. As shown in Table 2,
ll INSTI initially reactive results for these seroconversion sam-
les became non-reactive or showed signiﬁcant loss of test spot
ntensity when re-tested after IgM extraction. In contrast, late sero-
onversion and long term anti-HIV positive samples showed no loss
f INSTI test spot intensity following IgM extraction. Therefore, weical Virology 71 (2015) 67–72 71
conclude that the HIV-1 antibody detectable by INSTI in very early
seroconversion is primarily IgM. In total, 39 of the 41 INSTI reac-
tive commercial early seroconversion samples tested in this study
contained detectable anti-HIV-1 IgM antibodies according to the
sample panel datasheets. Of these, six samples (922-02, 922-03,
924-06, 943-06, 927-03, and 928-02) were consistent with Feibig
Class-III HIV-1 staging of primary infection.
Although a speciﬁc anti-HIV-1 IgM response is variable across
individuals with early HIV infection [11,20], and generally does not
persist beyond 3 months following its development in vivo [22], the
clinical application of a RPOCT assay such as the INSTI that detects
anti-HIV-1 IgM in addition to anti-HIV-1 IgG allows for reliable
early diagnosis of HIV infection.
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